[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"fda-warning-letters-search:[\"Ranir Corporation\",\"\",\"\",\"\",\"\",1]":3,"fda-latest-sync-dates":101},{"warningLetters":4,"total":100},[5,31,53,79],{"id":6,"raw":7,"subject":12,"body_html":14,"body_text":15,"firm_name":16,"letter_id":17,"created_at":18,"fei_number":19,"letter_url":20,"updated_at":21,"action_type":22,"case_status":23,"posted_date":24,"marcs_cms_no":25,"product_type":26,"closeout_date":19,"issuing_office":11,"recipient_name":27,"body_fetched_at":28,"delivery_method":29,"recipient_title":19,"reference_number":19,"action_taken_date":30,"medical_device_id":19,"response_letter_date":19},2571,[8,9,10,11,12,13,13,13],"\u003Ctime datetime=\"2022-07-19T13:20:00Z\">07\u002F19\u002F2022\u003C\u002Ftime>\n","\u003Ctime datetime=\"2022-07-08T04:00:00Z\">07\u002F08\u002F2022\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Ffree-range-vapor-llc-637146-07082022\">Free Range Vapor LLC\u003C\u002Fa>","Center for Tobacco Products","Family Smoking Prevention and Tobacco Control Act\u002FAdulterated\u002FMisbranded","","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS and Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Tobacco                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Monica Vondruska\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                    \n            \u003Cdd>Free Range Vapor LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>6418 Ward Rd.\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Arvada\u003C\u002Fspan>, \u003Cspan>CO\u003C\u002Fspan> \u003Cspan>80004-2461\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:info@freerangevapor.com\"> info@freerangevapor.com\u003C\u002Fa>\u003C\u002Fdd>\n    \u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:info@freerangevapors.com\"> info@freerangevapors.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Tobacco Products\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>July 8, 2022\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Dear Monica Vondruska:\u003C\u002Fp>\n\n\u003Cp>The Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) recently reviewed the website https:\u002F\u002Fwww.freerangevapors.com and determined that e-liquid products listed there are manufactured and offered for sale or distribution to customers in the United States.\u003C\u002Fp>\n\n\u003Cp>Under section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) (21 U.S.C. § 321(rr)), these products are tobacco products because they are made or derived from tobacco and intended for human consumption. Certain tobacco products, including e-liquids, are subject to FDA jurisdiction under section 901(b) of the FD&amp;C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. § 1100.1. Therefore, e-liquids are required to be in compliance with the requirements in the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>Please be aware that, effective August 8, 2016, FDA deemed additional products meeting the definition of a tobacco product, except accessories to these newly deemed products, to be subject to regulation under the FD&amp;C Act. These products include, but are not limited to, ENDS (including e-cigarettes and e-liquids), cigars, and pipe tobacco. See Final Rule, Deeming Tobacco Products To Be Subject to the Federal Food, Drug, and Cosmetic Act, as Amended by the Family Smoking Prevention and Tobacco Control Act; Restrictions on the Sale and Distribution of Tobacco Products and Required Warning Statements for Tobacco Products, 81 Fed. Reg. 28,974 (May 10, 2016), available at \u003Ca href=\"https:\u002F\u002Ffederalregister.gov\u002Fa\u002F2016-10685\">https:\u002F\u002Ffederalregister.gov\u002Fa\u002F2016-10685\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>Generally, to be legally marketed in the United States, the FD&amp;C Act requires “new tobacco products” to have a premarket authorization order in effect. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&amp;C Act; 21 U.S.C. § 387j(a)). Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&amp;C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&amp;C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&amp;C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&amp;C Act (21 U.S.C. § 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&amp;C Act (21 U.S.C. § 387e(j)(3)).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>New Tobacco Products Without Required Marketing Authorization are Adulterated and Misbranded\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Our review of the website https:\u002F\u002Fwww.freerangevapors.com revealed that you manufacture and offer for sale or distribution to customers in the United States the following e-liquid products without a marketing authorization order, including: Party Fowl; Pig in Mud; and Hot Llama.\u003C\u002Fp>\n\n\u003Cp>The e-liquid products listed above are new tobacco products because they were not commercially marketed in the United States as of February 15, 2007. These products do not have an FDA marketing authorization order in effect under section 910(c)(1)(A)(i) of the FD&amp;C Act and are not otherwise exempt from the marketing authorization requirement. Therefore, these products are adulterated under section 902(6)(A) of the FD&amp;C Act. In addition, these products are misbranded under section 903(a)(6) of the FD&amp;C Act because a notice or other information respecting these products were not provided as required by section 905(j) of the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion and Requested Actions\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your firm is a registered manufacturer with over 70 products. All new tobacco products on the market without the statutorily required premarket authorization are marketed unlawfully and are subject to enforcement action at FDA’s discretion. Products for which no application is pending, including, for example, those with a Marketing Denial Order and those for which no application was submitted, are among our highest enforcement priorities. For information on how FDA intends to prioritize enforcement resources with regard to the marketing of certain adulterated and misbranded ENDS and other deemed new tobacco products, please refer to the FDA’s guidance titled Enforcement Priorities for Electronic Nicotine Delivery Systems (ENDS) and Other Deemed Products on the Market Without Premarket Authorization, available at \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fenforcement-priorities-electronic-nicotine-delivery-system-ends-and-other-deemed-products-market\">https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fenforcement-priorities-electronic-nicotine-delivery-system-ends-and-other-deemed-products-market\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>It is your responsibility to ensure that your tobacco products and all related labeling and\u002For advertising on this website, on any other websites (including e-commerce, social networking, or search engine websites), in any other media in which you advertise, and in any retail establishments comply with each applicable provision of the FD&amp;C Act and FDA’s implementing regulations. Failure to address any violations of the FD&amp;C Act, 21 U.S.C. § 301 et seq., Chapter IX, relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, and 1143, may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&amp;C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated or misbranded may be detained or refused admission.\u003C\u002Fp>\n\n\u003Cp>The violations discussed in this letter do not necessarily constitute an exhaustive list. You should address any violations that are referenced above, as well as violations that are the same as or similar to those stated above, and promptly take any necessary actions to bring your tobacco products into compliance with the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>Please submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring your products into compliance, including the dates on which you discontinued the violative labeling, advertising, sale, and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&amp;C Act. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&amp;C Act through links on FDA’s homepage at \u003Ca href=\"http:\u002F\u002Fwww.fda.gov.\u002F\">http:\u002F\u002Fwww.fda.gov.\u003C\u002Fa>\u003C\u002Fp>\n\n\u003Cp>Please note your reference number, RW2201786, in your response and direct your response via email at CTPCompliance@fda.hhs.gov and to the following address:\u003C\u002Fp>\n\n\u003Cp>DPAL-WL Response, Office of Compliance and Enforcement\u003Cbr>\nFDA Center for Tobacco Products\u003Cbr>\nc\u002Fo Document Control Center\u003Cbr>\nBuilding 71, Room G335\u003Cbr>\n10903 New Hampshire Avenue\u003Cbr>\nSilver Spring, MD 20993-0002\u003C\u002Fp>\n\n\u003Cp>If you have any questions about the content of this letter, please contact Bryan Hills at (301) 796-9367 or via email at CTPCompliance@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Ann Simoneau, J.D.\u003Cbr>\nDirector\u003Cbr>\nOffice of Compliance and Enforcement\u003Cbr>\nCenter for Tobacco Products\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>VIA UPS and Electronic Mail\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>cc:\u003C\u002Fp>\n\n\u003Cp>Free Range Vapor, LLC\u003Cbr>\nAttn: Monica and Joe Vondruska\u003Cbr>\n31589 Hilltop Road\u003Cbr>\nGolden, CO 80004-7311\u003C\u002Fp>\n\n\u003Cp>Domains By Proxy, LLC\u003Cbr>\nabuse@domainsbyproxy.com\u003C\u002Fp>\n\n\u003Cp>GoDaddy.com, LLC\u003Cbr>\nabuse@godaddy.com\u003C\u002Fp>\n\n\u003Cp>Shopify, Inc.\u003Cbr>\nabuse@shopify.com\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS and Electronic Mail\n\nProduct:\n\nTobacco\n\nRecipient:\n\nRecipient Name\n\nMonica Vondruska\n\nFree Range Vapor LLC\n\n6418 Ward Rd.\n\nArvada, CO 80004-2461\n\nUnited States\n\ninfo@freerangevapor.com\n\ninfo@freerangevapors.com\n\nIssuing Office:\n\nCenter for Tobacco Products\n\nUnited States\n\nJuly 8, 2022\n\nWARNING LETTER\n\nDear Monica Vondruska:\n\nThe Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) recently reviewed the website https:\u002F\u002Fwww.freerangevapors.com and determined that e-liquid products listed there are manufactured and offered for sale or distribution to customers in the United States.\n\nUnder section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. § 321(rr)), these products are tobacco products because they are made or derived from tobacco and intended for human consumption. Certain tobacco products, including e-liquids, are subject to FDA jurisdiction under section 901(b) of the FD&C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. § 1100.1. Therefore, e-liquids are required to be in compliance with the requirements in the FD&C Act.\n\nPlease be aware that, effective August 8, 2016, FDA deemed additional products meeting the definition of a tobacco product, except accessories to these newly deemed products, to be subject to regulation under the FD&C Act. These products include, but are not limited to, ENDS (including e-cigarettes and e-liquids), cigars, and pipe tobacco. See Final Rule, Deeming Tobacco Products To Be Subject to the Federal Food, Drug, and Cosmetic Act, as Amended by the Family Smoking Prevention and Tobacco Control Act; Restrictions on the Sale and Distribution of Tobacco Products and Required Warning Statements for Tobacco Products, 81 Fed. Reg. 28,974 (May 10, 2016), available at https:\u002F\u002Ffederalregister.gov\u002Fa\u002F2016-10685.\n\nGenerally, to be legally marketed in the United States, the FD&C Act requires “new tobacco products” to have a premarket authorization order in effect. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&C Act; 21 U.S.C. § 387j(a)). Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&C Act (21 U.S.C. § 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&C Act (21 U.S.C. § 387e(j)(3)).\n\nNew Tobacco Products Without Required Marketing Authorization are Adulterated and Misbranded\n\nOur review of the website https:\u002F\u002Fwww.freerangevapors.com revealed that you manufacture and offer for sale or distribution to customers in the United States the following e-liquid products without a marketing authorization order, including: Party Fowl; Pig in Mud; and Hot Llama.\n\nThe e-liquid products listed above are new tobacco products because they were not commercially marketed in the United States as of February 15, 2007. These products do not have an FDA marketing authorization order in effect under section 910(c)(1)(A)(i) of the FD&C Act and are not otherwise exempt from the marketing authorization requirement. Therefore, these products are adulterated under section 902(6)(A) of the FD&C Act. In addition, these products are misbranded under section 903(a)(6) of the FD&C Act because a notice or other information respecting these products were not provided as required by section 905(j) of the FD&C Act.\n\nConclusion and Requested Actions\n\nYour firm is a registered manufacturer with over 70 products. All new tobacco products on the market without the statutorily required premarket authorization are marketed unlawfully and are subject to enforcement action at FDA’s discretion. Products for which no application is pending, including, for example, those with a Marketing Denial Order and those for which no application was submitted, are among our highest enforcement priorities. For information on how FDA intends to prioritize enforcement resources with regard to the marketing of certain adulterated and misbranded ENDS and other deemed new tobacco products, please refer to the FDA’s guidance titled Enforcement Priorities for Electronic Nicotine Delivery Systems (ENDS) and Other Deemed Products on the Market Without Premarket Authorization, available at https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fenforcement-priorities-electronic-nicotine-delivery-system-ends-and-other-deemed-products-market.\n\nIt is your responsibility to ensure that your tobacco products and all related labeling and\u002For advertising on this website, on any other websites (including e-commerce, social networking, or search engine websites), in any other media in which you advertise, and in any retail establishments comply with each applicable provision of the FD&C Act and FDA’s implementing regulations. Failure to address any violations of the FD&C Act, 21 U.S.C. § 301 et seq., Chapter IX, relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, and 1143, may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated or misbranded may be detained or refused admission.\n\nThe violations discussed in this letter do not necessarily constitute an exhaustive list. You should address any violations that are referenced above, as well as violations that are the same as or similar to those stated above, and promptly take any necessary actions to bring your tobacco products into compliance with the FD&C Act.\n\nPlease submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring your products into compliance, including the dates on which you discontinued the violative labeling, advertising, sale, and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&C Act. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&C Act through links on FDA’s homepage at http:\u002F\u002Fwww.fda.gov.\n\nPlease note your reference number, RW2201786, in your response and direct your response via email at CTPCompliance@fda.hhs.gov and to the following address:\n\nDPAL-WL Response, Office of Compliance and Enforcement\n\nFDA Center for Tobacco Products\n\nc\u002Fo Document Control Center\n\nBuilding 71, Room G335\n\n10903 New Hampshire Avenue\n\nSilver Spring, MD 20993-0002\n\nIf you have any questions about the content of this letter, please contact Bryan Hills at (301) 796-9367 or via email at CTPCompliance@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nAnn Simoneau, J.D.\n\nDirector\n\nOffice of Compliance and Enforcement\n\nCenter for Tobacco Products\n\nVIA UPS and Electronic Mail\n\ncc:\n\nFree Range Vapor, LLC\n\nAttn: Monica and Joe Vondruska\n\n31589 Hilltop Road\n\nGolden, CO 80004-7311\n\nDomains By Proxy, LLC\n\nabuse@domainsbyproxy.com\n\nGoDaddy.com, LLC\n\nabuse@godaddy.com\n\nShopify, Inc.\n\nabuse@shopify.com","Free Range Vapor LLC","free-range-vapor-llc-637146-07082022","2026-08-18T06:42:29.262718+00:00",null,"https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Ffree-range-vapor-llc-637146-07082022","2026-10-26T08:08:43.086688+00:00","Warning Letter","Issued","2022-07-19","637146","Tobacco","Monica Vondruska","2026-08-20T01:45:03.452+00:00","VIA UPS and Electronic Mail","2022-07-08",{"id":32,"raw":33,"subject":38,"body_html":39,"body_text":40,"firm_name":41,"letter_id":42,"created_at":43,"fei_number":19,"letter_url":44,"updated_at":45,"action_type":22,"case_status":23,"posted_date":46,"marcs_cms_no":47,"product_type":48,"closeout_date":19,"issuing_office":37,"recipient_name":49,"body_fetched_at":50,"delivery_method":51,"recipient_title":19,"reference_number":19,"action_taken_date":52,"medical_device_id":19,"response_letter_date":19},1092,[34,35,36,37,38,13,13,13],"\u003Ctime datetime=\"2025-01-14T14:20:00Z\">01\u002F14\u002F2025\u003C\u002Ftime>\n","\u003Ctime datetime=\"2024-12-06T05:00:00Z\">12\u002F06\u002F2024\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Frandox-laboratories-limited-696569-12062024\">Randox Laboratories Limited\u003C\u002Fa>","Center for Devices and Radiological Health","CGMP\u002FQSR\u002FMedical Devices\u002FAdulterated","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Steven Peter FitzGerald\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Founder and Managing Director \u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Randox Laboratories Limited\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>30 Randalstown Road\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Antrim\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>BT41 4FL\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United Kingdom\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:peter.fitzgerald@randox.com\"> peter.fitzgerald@randox.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Devices and Radiological Health\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>December 6, 2024\u003C\u002Fp>\u003Cp>Dear Mr. Steven Peter FitzGerald:\u003C\u002Fp>\u003Cp>During an inspection of your firm located in Antrim, United Kingdom on August 5, 2024 through August 8, 2024, an investigator from the United States Food and Drug Administration (FDA) determined that your firm manufactures the RX series test systems, including the RX daytona, the RX daytona + (plus), and the RX imola test systems. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or function of the body.\u003C\u002Fp>\u003Cp>This inspection revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, \u003Cu>Code of Federal Regulations\u003C\u002Fu> (CFR), Part 820.\u003C\u002Fp>\u003Cp>We received responses from Linda A Magee, Chief Operating Officer dated August 29. 2024, and Oisin Quinn, Quality Improvement Manager dated November 8, 2024 concerning our investigator’s observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, which was issued to your firm. We address these responses below, in relation to each of the noted violations. These violations include, but are not limited to, the following:\u003C\u002Fp>\u003Cp>1. Failure to adequately establish and maintain procedures for validating device design, including appropriate risk analysis, as required by 21 CFR 820.30(g). For example, your firm has initiated five Class II Recalls, beginning in 2018 (Event IDs 81746, 86236, 91097, 92650, 93775), related to assay reagents from the previously used assays carrying over to the subsequent assay test, which caused erroneous results of the subsequent assay conducted on your RX series analyzers, including RX daytona and RX imola. Your firm’s procedure, Risk Management, RQA-1707, Revision O, drafted on June 6, 2023, section 5.1.3.4 Post Market surveillance, states “The Risk Management Report must be updated with any new hazards or hazardous situations identified and or any additional control measures that are required”. Additionally, section 5.2.4 Risk Control requires that control measures should be implemented using “\u003Cstrong>(b)(4)\u003C\u002Fstrong>,” in that order of priority. However, your firm has not conducted adequate risk analysis nor identified adequate control measures to address the risks of reagents from the precedent assays carrying over to the subsequent assay conducted on the RX series analyzers to ensure the devices (i.e., manufactured assays tested on RX series analyzers) meet their intended use.\u003C\u002Fp>\u003Cp>We reviewed your firm’s responses and conclude that they are not adequate. Your firm has identified that the root cause is related to ambiguity in your risk analysis procedures, lack of clear responsibility for the activities, and that maintenance of the risk management files and not been effective. Your firm states that you have reviewed and updated the risk management files for the recalled products, however, copies of those files were not provided for review because they are currently under review by specified teams at your firm. An estimated date of completion was not provided.\u003C\u002Fp>\u003Cp>Your firm also provided Risk Management Report for RX Series Analyzers – Automated RX modena, RX daytona+, RX daytona, RX imola, RX monaco, dated September 30, 2024 and Risk Analysis for RX Series Analyzers – Automated, revision number 4, approved on September 30, 2024. A carryover and contamination category was added to analyzer risk analysis. The risk evaluation before \u003Cstrong>(b)(4)\u003C\u002Fstrong>.” However, no information was provided to support \u003Cstrong>(b)(4)\u003C\u002Fstrong> as required by RQA-1707.\u003C\u002Fp>\u003Cp>Your firm provided a revised job description for the Device Documentation Specialist (JD1402), who is within the \u003Cstrong>(b)(4)\u003C\u002Fstrong> of RQA-1707, revision Q, drafted September 20, 2024. The procedure has been revised to require the Quality Assurance department to review \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Post Market Surveillance, RQA-1664, revision M, drafted September 20, 2024 was revised to, among other things, define that the Quality Assurance Department is responsible \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Control of Non-Conforming Product or Process, RGP-2032, revision U, drafted November 7, 2024 was revised to include responsibility for Quality Assurance Department for \u003Cstrong>(b)(4)\u003C\u002Fstrong>. However, RQA-1707, RQA-1664, and RGP-2032 do not reference the Device Documentation Specialist. Therefore, it is unclear how the revised job description will prevent similar failures in the future. Your firm stated retraining on RQA-1707, RQA-1664, and RGP-2032 was completed and provided examples for how a completion of training event was documented. However, information on the verification or validation of the retraining (a corrective action) to ensure that the action is effective was not provided. Your firm plans to \u003Cstrong>(b)(4)\u003C\u002Fstrong>. However, evidence that appropriate control measures will be applied has not been provided. Your firm should provide an update on this review and any remediation efforts needed. You firm also stated that RGP-1002 has been updated but FDA was unable to open this file to review and therefore the Agency unable is unable to determine whether this action is effective.\u003C\u002Fp>\u003Cp>2. Failure to establish and maintain adequate procedures for implementing corrective and preventive action, as required by 21 CFR 820.100(a). For example, CAPA NCP INC612, was initiated on October 16, 2023, due to a customer complaint related to issues when running Copper assay on a RX daytona + analyzer. Your firm confirmed the testing of total protein carried over to the subsequent copper assay, causing falsely elevated Copper results. The root cause description states, “Carryover from both cuvettes and pipettes,” but fails to identify the underlying cause of why the reagent from the previously used assay carried over to the subsequent assay. The CAPA was closed on May 20, 2024, with the correction, “Technical bulletin RXTB-0121 to be updated with as a result of the testing recommending that Copper and Total protein on the same machine.” Since December 2018, your firm has initiated five US market Class II Recalls (Event IDs 81746, 86236, 91097, 92650, 93775) due to erroneous results caused by reagent carryover and, in each your firm has issued an updated Technical Bulletin for carryover avoidance (RXTB-0083, issued February 16, 2018 and RXTB-0098, issued November 20, 2018; RXTB-0121, issued July 31, 2020; RXTB-0136, issued September 22, 2022; RXTB-0148, issued June 6, 2023; RXTB-0148, issued November 22, 2023). The bulletin currently includes a list of over 50 combinations of assays to avoid running in sequence. CAPA #NCP INC612 fails to identify the action(s) needed to correct and prevent recurrence of carryover of assays run on the RX series analyzers. Additionally, activities to ensure the effectiveness of the corrective actions were not identified. Your firm states “Confirm no further complaints since bulletin” but fails to verify or validate the corrective and preventive action to ensure that such action is effective.\u003C\u002Fp>\u003Cp>We reviewed your firm’s responses and conclude that they are not adequate. Your firm has identified the root cause is related to inadequate procedure and absence of dedicated training resources on root cause analysis for the staff to perform root cause analysis adequately and effectively. Your firm determined the actual root cause for the carryover event from CAPA #NCP INC612 is because of inadequate cleaning of the pipette\u002Fcuvette after programmed cleaning on the automated analyzer so the remaining residue of the reagents from Total Protein assay, which contains copper, impacted the subsequent Copper assay. Your firm has not identified corrective and prevention actions for CAPA #NCP INC612 and has not provided information on how you will verify or validate the corrective and preventive action is effective.\u003C\u002Fp>\u003Cp>Your firm has updated the CAPA procedure “Control of Non-Conforming Product or Process, RGP-2032, revision U, drafted November 7, 2024” to include reference to root cause analysis training material and created training slides “QAT 2.17.pptx” for performing root-cause analysis. Your firm stated training on RGP-2032 and QAT 2.17 was completed and provided an example for how the completion of training event documented. However, information on the verification or validation of the retraining (a corrective action) to ensure that the action is effective was not provided.\u003C\u002Fp>\u003Cp>Your firm proposed \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Your firm should provide an update on this review and any remediation efforts needed.\u003C\u002Fp>\u003Cp>Your firm initiated a CAPA (qNCP 1394) dated August 29, 2024 to determine \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Your firm has yet identified the root cause for causing the inadequate cleaning which your firm stated in an email dated November 8, 2024, is the common root cause of all the initiated recalls related to carryover on the RX series instruments. Your firm has yet to define actions to prevent recurrence.\u003C\u002Fp>\u003Cp>Your firm plans to review CAPAs and root cause \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Your firm should provide an update on this review and any remediation efforts needed.\u003C\u002Fp>\u003Cp>Other federal agencies may take your compliance with the FD&amp;C Act and its implementation regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed.\u003C\u002Fp>\u003Cp>Additionally, based on information provided to the investigator during and following the inspection, it appears that your establishment registrations and device listings are incorrect and should be further clarified. During teleconferences following the inspection with the investigator on September 5 and 11, 2024, you promised to evaluate \u003Cstrong>(b)(4)\u003C\u002Fstrong>. However, as of the date of this letter your registration and listing data remains unchanged.\u003C\u002Fp>\u003Cp>Please notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, including an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective action (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Please provide a translation of documentation not in English to facilitate our review. We will notify you regarding the adequacy of your firm’s response(s) and the need to re-inspect your firm’s facility to verify that the appropriate corrections and\u002For corrective actions have been made. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration as part of your response.\u003C\u002Fp>\u003Cp>Your firm’s response should be sent via email to CDRHWarningLetterResponses@fda.hhs.gov. \u003Cstrong>Refer to CMS case #696569 when replying\u003C\u002Fstrong>. If you have any questions about the contents of this letter, please contact: I-Lin Wu at i-lin.wu@fda.hhs.gov.\u003C\u002Fp>\u003Cp>Finally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\u003C\u002Fp>\u003Cp>Sincerely yours,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Courtney H. Lias, Ph.D.\u003Cbr>Director\u003Cbr>OHT7: Office of In Vitro Diagnostic Devices\u003Cbr>Office of Product Evaluation and Quality\u003Cbr>Center for Devices and Radiological Health\u003C\u002Fp>\u003Cp>CC:\u003Cbr>Cheryl OHagan\u003Cbr>US Agent\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA Electronic Mail\n\nProduct:\n\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nSteven Peter FitzGerald\n\nRecipient Title\n\nFounder and Managing Director\n\nRandox Laboratories Limited\n\n30 Randalstown Road\n\nAntrim\n\nBT41 4FL\n\nUnited Kingdom\n\npeter.fitzgerald@randox.com\n\nIssuing Office:\n\nCenter for Devices and Radiological Health\n\nUnited States\n\nWARNING LETTER\nDecember 6, 2024\nDear Mr. Steven Peter FitzGerald:\nDuring an inspection of your firm located in Antrim, United Kingdom on August 5, 2024 through August 8, 2024, an investigator from the United States Food and Drug Administration (FDA) determined that your firm manufactures the RX series test systems, including the RX daytona, the RX daytona + (plus), and the RX imola test systems. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or function of the body.\nThis inspection revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820.\nWe received responses from Linda A Magee, Chief Operating Officer dated August 29. 2024, and Oisin Quinn, Quality Improvement Manager dated November 8, 2024 concerning our investigator’s observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, which was issued to your firm. We address these responses below, in relation to each of the noted violations. These violations include, but are not limited to, the following:\n1. Failure to adequately establish and maintain procedures for validating device design, including appropriate risk analysis, as required by 21 CFR 820.30(g). For example, your firm has initiated five Class II Recalls, beginning in 2018 (Event IDs 81746, 86236, 91097, 92650, 93775), related to assay reagents from the previously used assays carrying over to the subsequent assay test, which caused erroneous results of the subsequent assay conducted on your RX series analyzers, including RX daytona and RX imola. Your firm’s procedure, Risk Management, RQA-1707, Revision O, drafted on June 6, 2023, section 5.1.3.4 Post Market surveillance, states “The Risk Management Report must be updated with any new hazards or hazardous situations identified and or any additional control measures that are required”. Additionally, section 5.2.4 Risk Control requires that control measures should be implemented using “(b)(4),” in that order of priority. However, your firm has not conducted adequate risk analysis nor identified adequate control measures to address the risks of reagents from the precedent assays carrying over to the subsequent assay conducted on the RX series analyzers to ensure the devices (i.e., manufactured assays tested on RX series analyzers) meet their intended use.\nWe reviewed your firm’s responses and conclude that they are not adequate. Your firm has identified that the root cause is related to ambiguity in your risk analysis procedures, lack of clear responsibility for the activities, and that maintenance of the risk management files and not been effective. Your firm states that you have reviewed and updated the risk management files for the recalled products, however, copies of those files were not provided for review because they are currently under review by specified teams at your firm. An estimated date of completion was not provided.\nYour firm also provided Risk Management Report for RX Series Analyzers – Automated RX modena, RX daytona+, RX daytona, RX imola, RX monaco, dated September 30, 2024 and Risk Analysis for RX Series Analyzers – Automated, revision number 4, approved on September 30, 2024. A carryover and contamination category was added to analyzer risk analysis. The risk evaluation before (b)(4).” However, no information was provided to support (b)(4) as required by RQA-1707.\nYour firm provided a revised job description for the Device Documentation Specialist (JD1402), who is within the (b)(4) of RQA-1707, revision Q, drafted September 20, 2024. The procedure has been revised to require the Quality Assurance department to review (b)(4). Post Market Surveillance, RQA-1664, revision M, drafted September 20, 2024 was revised to, among other things, define that the Quality Assurance Department is responsible (b)(4). Control of Non-Conforming Product or Process, RGP-2032, revision U, drafted November 7, 2024 was revised to include responsibility for Quality Assurance Department for (b)(4). However, RQA-1707, RQA-1664, and RGP-2032 do not reference the Device Documentation Specialist. Therefore, it is unclear how the revised job description will prevent similar failures in the future. Your firm stated retraining on RQA-1707, RQA-1664, and RGP-2032 was completed and provided examples for how a completion of training event was documented. However, information on the verification or validation of the retraining (a corrective action) to ensure that the action is effective was not provided. Your firm plans to (b)(4). However, evidence that appropriate control measures will be applied has not been provided. Your firm should provide an update on this review and any remediation efforts needed. You firm also stated that RGP-1002 has been updated but FDA was unable to open this file to review and therefore the Agency unable is unable to determine whether this action is effective.\n2. Failure to establish and maintain adequate procedures for implementing corrective and preventive action, as required by 21 CFR 820.100(a). For example, CAPA NCP INC612, was initiated on October 16, 2023, due to a customer complaint related to issues when running Copper assay on a RX daytona + analyzer. Your firm confirmed the testing of total protein carried over to the subsequent copper assay, causing falsely elevated Copper results. The root cause description states, “Carryover from both cuvettes and pipettes,” but fails to identify the underlying cause of why the reagent from the previously used assay carried over to the subsequent assay. The CAPA was closed on May 20, 2024, with the correction, “Technical bulletin RXTB-0121 to be updated with as a result of the testing recommending that Copper and Total protein on the same machine.” Since December 2018, your firm has initiated five US market Class II Recalls (Event IDs 81746, 86236, 91097, 92650, 93775) due to erroneous results caused by reagent carryover and, in each your firm has issued an updated Technical Bulletin for carryover avoidance (RXTB-0083, issued February 16, 2018 and RXTB-0098, issued November 20, 2018; RXTB-0121, issued July 31, 2020; RXTB-0136, issued September 22, 2022; RXTB-0148, issued June 6, 2023; RXTB-0148, issued November 22, 2023). The bulletin currently includes a list of over 50 combinations of assays to avoid running in sequence. CAPA #NCP INC612 fails to identify the action(s) needed to correct and prevent recurrence of carryover of assays run on the RX series analyzers. Additionally, activities to ensure the effectiveness of the corrective actions were not identified. Your firm states “Confirm no further complaints since bulletin” but fails to verify or validate the corrective and preventive action to ensure that such action is effective.\nWe reviewed your firm’s responses and conclude that they are not adequate. Your firm has identified the root cause is related to inadequate procedure and absence of dedicated training resources on root cause analysis for the staff to perform root cause analysis adequately and effectively. Your firm determined the actual root cause for the carryover event from CAPA #NCP INC612 is because of inadequate cleaning of the pipette\u002Fcuvette after programmed cleaning on the automated analyzer so the remaining residue of the reagents from Total Protein assay, which contains copper, impacted the subsequent Copper assay. Your firm has not identified corrective and prevention actions for CAPA #NCP INC612 and has not provided information on how you will verify or validate the corrective and preventive action is effective.\nYour firm has updated the CAPA procedure “Control of Non-Conforming Product or Process, RGP-2032, revision U, drafted November 7, 2024” to include reference to root cause analysis training material and created training slides “QAT 2.17.pptx” for performing root-cause analysis. Your firm stated training on RGP-2032 and QAT 2.17 was completed and provided an example for how the completion of training event documented. However, information on the verification or validation of the retraining (a corrective action) to ensure that the action is effective was not provided.\nYour firm proposed (b)(4). Your firm should provide an update on this review and any remediation efforts needed.\nYour firm initiated a CAPA (qNCP 1394) dated August 29, 2024 to determine (b)(4). Your firm has yet identified the root cause for causing the inadequate cleaning which your firm stated in an email dated November 8, 2024, is the common root cause of all the initiated recalls related to carryover on the RX series instruments. Your firm has yet to define actions to prevent recurrence.\nYour firm plans to review CAPAs and root cause (b)(4). Your firm should provide an update on this review and any remediation efforts needed.\nOther federal agencies may take your compliance with the FD&C Act and its implementation regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed.\nAdditionally, based on information provided to the investigator during and following the inspection, it appears that your establishment registrations and device listings are incorrect and should be further clarified. During teleconferences following the inspection with the investigator on September 5 and 11, 2024, you promised to evaluate (b)(4). However, as of the date of this letter your registration and listing data remains unchanged.\nPlease notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, including an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective action (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Please provide a translation of documentation not in English to facilitate our review. We will notify you regarding the adequacy of your firm’s response(s) and the need to re-inspect your firm’s facility to verify that the appropriate corrections and\u002For corrective actions have been made. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration as part of your response.\nYour firm’s response should be sent via email to CDRHWarningLetterResponses@fda.hhs.gov. Refer to CMS case #696569 when replying. If you have any questions about the contents of this letter, please contact: I-Lin Wu at i-lin.wu@fda.hhs.gov.\nFinally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\nSincerely yours,\n\u002FS\u002F\nCourtney H. Lias, Ph.D.\nDirector\nOHT7: Office of In Vitro Diagnostic Devices\nOffice of Product Evaluation and Quality\nCenter for Devices and Radiological Health\nCC:\nCheryl OHagan\nUS Agent","Randox Laboratories Limited","randox-laboratories-limited-696569-12062024","2026-08-18T06:42:28.856152+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Frandox-laboratories-limited-696569-12062024","2026-10-26T08:09:47.070417+00:00","2025-01-14","696569","Medical Devices","Steven Peter FitzGerald","2026-08-19T17:05:02.173+00:00","VIA Electronic Mail","2024-12-06",{"id":54,"raw":55,"subject":60,"body_html":62,"body_text":63,"firm_name":64,"letter_id":65,"created_at":66,"fei_number":19,"letter_url":67,"updated_at":68,"action_type":22,"case_status":69,"posted_date":70,"marcs_cms_no":71,"product_type":72,"closeout_date":73,"issuing_office":74,"recipient_name":75,"body_fetched_at":76,"delivery_method":77,"recipient_title":19,"reference_number":19,"action_taken_date":78,"medical_device_id":19,"response_letter_date":19},2324,[56,57,58,59,60,13,61,13],"\u003Ctime datetime=\"2022-11-22T14:20:00Z\">11\u002F22\u002F2022\u003C\u002Ftime>\n","\u003Ctime datetime=\"2022-10-18T04:00:00Z\">10\u002F18\u002F2022\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Frosebuds-ranch-and-garden-llc-628567-10182022\">Rosebud&#039;s Ranch and Garden, LLC\u003C\u002Fa>"," Division of Human and Animal Food Operations East V ","New Drug\u002FMisbranded","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Frosebuds-ranch-and-garden-llc-628567-03312023\">\u003Ctime datetime=\"2023-04-07T04:00:00Z\">04\u002F07\u002F2023\u003C\u002Ftime>\n\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>United Parcel Service\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs\u003Cbr>Food &amp; Beverages                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Amber R. Stephenson\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Owner\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Rosebud's Ranch and Garden, LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>122 W High St.\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Piqua\u003C\u002Fspan>, \u003Cspan>OH\u003C\u002Fspan> \u003Cspan>45356\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd> Division of Human and Animal Food Operations East V \u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>Warning Letter # 628567\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>10\u002F18\u002F2022\u003C\u002Fp>\n\n\u003Cp>Dear Ms. Stephenson:\u003C\u002Fp>\n\n\u003Cp>This is to advise you that the Food and Drug Administration (FDA) reviewed your website at the Internet address www.rosebudsrealfood.com and your social media website at www.facebook.com\u002FRosebudsRealFood in June and August 2022, from which sites you take orders for Domestic Divas – Colds and Flu (Tea), Domestic Divas - No Pain No Gain Tea, Green Feather Homestead Mad As A Hatter Chai Tea, Rosebud’s Natural Seasonings Elderberry Syrup Kit, Rosebud’s Elderberry Lemonade, Rosebud’s Herbs &amp; Spices Sencha Tea, Rosebud’s Natural Seasonings Jane’s Italian, Rosebud’s Fruit Butters Peach Blueberry, Rosebud’s Real Food Raw! Habanero Sriracha, and Rosebud’s Real Food Supertonic! Sriracha. The claims on your websites establish the products are drugs under section 201(g)(1)(B) of the Federal Food, Drug, and Cosmetic Act (the Act) [21 U.S.C. 321(g)(1)(B)] because they are intended for use in the cure, mitigation, treatment, or prevention of disease. As explained further below, introducing or delivering these products for introduction into interstate commerce for such uses violates the Act. You can find the FD&amp;C Act and FDA regulations through links on FDA’s home page at \u003Ca>www.fda.gov.\u003C\u002Fa>\u003C\u002Fp>\n\n\u003Cp>Examples of some of the claims that provide evidence that your products are intended for use as drugs include:\u003C\u002Fp>\n\n\u003Cp>Domestic Divas - Colds and Flu (Tea)\u003Cbr>\n&nbsp; &nbsp; “Eases the discomfort of a cold or flu”\u003C\u002Fp>\n\n\u003Cp>Domestic Divas - No Pain No Gain Tea\u003Cbr>\n&nbsp; &nbsp; “Eases Muscular Pain”\u003C\u002Fp>\n\n\u003Cp>Green Feather Homestead Mad As A Hatter Chai Tea\u003Cbr>\n&nbsp; &nbsp; “balancing to blood sugar”\u003Cbr>\n\u003Cbr>\nRosebud’s Natural Seasonings Elderberry Syrup Kit: From the product label, as shown on an image on your website at www.rosebudsrealfood.com\u002Fproducts\u002Felderberry-syrupkit?_pos=1&amp;_sid=4f1ea37c2&amp;_ss=r:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>“Standard dose is ½ tsp - 1 tsp for kids and ½ - 1 tablespoon for adults. If the flu does strike, take the normal dose every 2-3 hours instead of once a day until symptoms disappear”\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>Rosebud’s Elderberry Lemonade, Rosebud’s Natural Seasonings Elderberry Syrup Kit (Elderberry ingredient): www.facebook.com\u002FRosebudsRealFood\u003C\u002Fp>\n\n\u003Cp>Facebook Post Date February 3, 2022\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>&nbsp;“‘Health benefits of the elder plant [elderberry] include naturally improving sinus issues, nerve pain, inflammation, chronic fatigue, allergies, constipation and even cancer. When used within the first 48 hours of onset of symptoms, the extract may even help relieve and shorten the duration of cold and flu symptoms as well.”\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>Facebook Post Date September 3, 2021\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>&nbsp;“Cancer Preventer”\u003C\u002Fli>\n\t\u003Cli>&nbsp;“Blood Sugar Balancer”\u003C\u002Fli>\n\t\u003Cli>&nbsp;“Cold &amp; Flu Fighter”\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>Rosebud’s Herbs &amp; Spices Sencha Tea: www.facebook.com\u002FRosebudsRealFood\u003C\u002Fp>\n\n\u003Cp>Facebook Post Date January 4, 2022\u003C\u002Fp>\n\n\u003Cp>“Potential benefits of sencha green tea include:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>&nbsp;anti-cancer properties\u003C\u002Fli>\n\t\u003Cli>&nbsp;prevention of neurodegenerative diseases\u003C\u002Fli>\n\t\u003Cli>&nbsp;anti-inflammatory properties\u003C\u002Fli>\n\t\u003Cli>&nbsp;lowering bad cholesterol\u003C\u002Fli>\n\t\u003Cli>&nbsp;anti-bacterial properties\u003C\u002Fli>\n\t\u003Cli>&nbsp;prevention of some bacterial and virus infections\u003C\u002Fli>\n\t\u003Cli>&nbsp;preventing tooth decay”\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>Real Food Raw! Habanero Sriracha, Natural Seasonings Jane’s Italian, and Real Food Supertonic! Sriracha (all of which contain garlic as an ingredient): www.facebook.com\u002FRosebudsRealFood\u003C\u002Fp>\n\n\u003Cp>Facebook Post Date January 22, 2022\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>&nbsp;“Garlic is antiviral, antibacterial, antifungal (including anti-mold), anti-parasitic, and rich in the phytochemical allicin, a sulfur compound that prevents disease.”\u003C\u002Fli>\n\t\u003Cli>&nbsp;“Garlic kills off pathogens such as viruses and unproductive bacteria, which are behind so many mystery and chronic illnesses and symptoms.”\u003C\u002Fli>\n\t\u003Cli>&nbsp;“Garlic helps fight colds, flus, strep throat, pneumonia-causing bacteria, and viral-related cancers.”\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>Facebook Post Date January 9, 2022\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>&nbsp;“Eat some garlic and lower that blood pressure!”\u003C\u002Fli>\n\t\u003Cli>&nbsp;“Garlic has anti-inflammatory benefits and helps blood flow more easily through the body. Several studies found that blood pressure was lowered by 10%!!!!”\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>Rosebud’s Elderberry Lemonade and Rosebud’s Fruit Butters Peach Blueberry (which contain lemon): www.facebook.com\u002FRosebudsRealFood\u003C\u002Fp>\n\n\u003Cp>Facebook Post Date February 19, 2022\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>&nbsp;“[P]hytochemicals called limonoids in lemons and limes actually bond the vitamin C and calcium together, so that wherever one goes in the body, the other rides along. This enhances the bioavailability of each, and also creates alkalinity in the body to help prevent the growth of almost every type of cancer”\u003C\u002Fli>\n\t\u003Cli>&nbsp;“The antioxidant flavonoids in lemons and limes are another ally in fighting disease. And when you’re dealing with a cold, flu, bronchitis, or pneumonia, lemon is one of the most effective mucus expellers you can find.”\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>Your products are not generally recognized as safe and effective for the above referenced uses and, therefore, the products are “new drugs” under section 201(p) of the Act [21 U.S.C. 321(p)]. With certain exceptions not applicable here, new drugs may not be legally introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in sections 301(d) and 505(a) of the Act [21 U.S.C. 331(d), 355(a)]. FDA approves a new drug on the basis of scientific data and information demonstrating that the drug is safe and effective.\u003C\u002Fp>\n\n\u003Cp>A drug is misbranded under section 502(f)(1) of the Act [21 U.S.C. 352(f)(1)] if the drug fails to bear adequate directions for its intended use(s). “Adequate directions for use” means directions under which a layperson can use a drug safely and for the purposes for which it is intended (21 CFR 201.5). Prescription drugs, as defined in section 503(b)(1)(A) of the Act [21 U.S.C. 353(b)(1)(A)], can only be used safely at the direction, and under the supervision, of a licensed practitioner.\u003C\u002Fp>\n\n\u003Cp>Your products Rosebud’s Natural Seasonings Elderberry Syrup Kit, Rosebud’s Elderberry Lemonade, Rosebud’s Real Food Raw! Habanero Sriracha, Rosebud’s Natural Seasonings Jane’s Italian, Rosebud’s Fruit Butters Peach Blueberry, Rosebud’s Herbs &amp; Spices Sencha Tea and Rosebud’s Real Food Supertonic! Sriracha are intended for treatment of one or more diseases that are not amenable to self-diagnosis or treatment without the supervision of a licensed practitioner. Therefore, it is impossible to write adequate directions for a layperson to use your product safely for its intended purpose. Accordingly, Rosebud’s Natural Seasonings Elderberry Syrup Kit, Rosebud’s Elderberry Lemonade, Rosebud’s Real Food Raw! Habanero Sriracha, Rosebud’s Natural Seasonings Jane’s Italian, Rosebud’s Fruit Butters Peach Blueberry, Rosebud’s Herbs &amp; Spices Sencha Tea, and Rosebud’s Real Food Supertonic! Sriracha fail to bear adequate directions for their intended use and, therefore, the products are misbranded under section 502(f)(1) of the Act [21 U.S.C. 352(f)(1)]. The introduction or delivery for introduction into interstate commerce of these misbranded drugs violates section 301(a) of the Act [21 U.S.C. 331(a)].\u003C\u002Fp>\n\n\u003Cp>This letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\u003C\u002Fp>\n\n\u003Cp>Please notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within 15 working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\n\n\u003Cp>Your reply should be addressed to the U.S. Food and Drug Administration; Attn: Christopher N. Dedeaux, Compliance Officer, via email at ORAHAFEAST5FirmResponses@fda.hhs.gov or at 404 BNA Drive, Suite 500, Nashville, TN 37217. You may reach Mr. Dedeaux at 504-846-6122 or via email at Christopher.Dedeaux@fda.hhs.gov if you have any questions about this matter.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Steven B. Barber\u003Cbr>\nDirector, Division V\u003Cbr>\nOffice of Human and Animal Foods Operations-East\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nUnited Parcel Service\n\nProduct:\n\nDrugs\nFood & Beverages\n\nRecipient:\n\nRecipient Name\n\nAmber R. Stephenson\n\nRecipient Title\n\nOwner\n\nRosebud's Ranch and Garden, LLC\n\n122 W High St.\n\nPiqua, OH 45356\n\nUnited States\n\nIssuing Office:\n\nDivision of Human and Animal Food Operations East V\n\nUnited States\n\nWarning Letter # 628567\n\n10\u002F18\u002F2022\n\nDear Ms. Stephenson:\n\nThis is to advise you that the Food and Drug Administration (FDA) reviewed your website at the Internet address www.rosebudsrealfood.com and your social media website at www.facebook.com\u002FRosebudsRealFood in June and August 2022, from which sites you take orders for Domestic Divas – Colds and Flu (Tea), Domestic Divas - No Pain No Gain Tea, Green Feather Homestead Mad As A Hatter Chai Tea, Rosebud’s Natural Seasonings Elderberry Syrup Kit, Rosebud’s Elderberry Lemonade, Rosebud’s Herbs & Spices Sencha Tea, Rosebud’s Natural Seasonings Jane’s Italian, Rosebud’s Fruit Butters Peach Blueberry, Rosebud’s Real Food Raw! Habanero Sriracha, and Rosebud’s Real Food Supertonic! Sriracha. The claims on your websites establish the products are drugs under section 201(g)(1)(B) of the Federal Food, Drug, and Cosmetic Act (the Act) [21 U.S.C. 321(g)(1)(B)] because they are intended for use in the cure, mitigation, treatment, or prevention of disease. As explained further below, introducing or delivering these products for introduction into interstate commerce for such uses violates the Act. You can find the FD&C Act and FDA regulations through links on FDA’s home page at www.fda.gov.\n\nExamples of some of the claims that provide evidence that your products are intended for use as drugs include:\n\nDomestic Divas - Colds and Flu (Tea)\n\n“Eases the discomfort of a cold or flu”\n\nDomestic Divas - No Pain No Gain Tea\n\n“Eases Muscular Pain”\n\nGreen Feather Homestead Mad As A Hatter Chai Tea\n\n“balancing to blood sugar”\n\nRosebud’s Natural Seasonings Elderberry Syrup Kit: From the product label, as shown on an image on your website at www.rosebudsrealfood.com\u002Fproducts\u002Felderberry-syrupkit?_pos=1&_sid=4f1ea37c2&_ss=r:\n\n“Standard dose is ½ tsp - 1 tsp for kids and ½ - 1 tablespoon for adults. If the flu does strike, take the normal dose every 2-3 hours instead of once a day until symptoms disappear”\n\nRosebud’s Elderberry Lemonade, Rosebud’s Natural Seasonings Elderberry Syrup Kit (Elderberry ingredient): www.facebook.com\u002FRosebudsRealFood\n\nFacebook Post Date February 3, 2022\n\n“‘Health benefits of the elder plant [elderberry] include naturally improving sinus issues, nerve pain, inflammation, chronic fatigue, allergies, constipation and even cancer. When used within the first 48 hours of onset of symptoms, the extract may even help relieve and shorten the duration of cold and flu symptoms as well.”\n\nFacebook Post Date September 3, 2021\n\n“Cancer Preventer”\n\n“Blood Sugar Balancer”\n\n“Cold & Flu Fighter”\n\nRosebud’s Herbs & Spices Sencha Tea: www.facebook.com\u002FRosebudsRealFood\n\nFacebook Post Date January 4, 2022\n\n“Potential benefits of sencha green tea include:\n\nanti-cancer properties\n\nprevention of neurodegenerative diseases\n\nanti-inflammatory properties\n\nlowering bad cholesterol\n\nanti-bacterial properties\n\nprevention of some bacterial and virus infections\n\npreventing tooth decay”\n\nReal Food Raw! Habanero Sriracha, Natural Seasonings Jane’s Italian, and Real Food Supertonic! Sriracha (all of which contain garlic as an ingredient): www.facebook.com\u002FRosebudsRealFood\n\nFacebook Post Date January 22, 2022\n\n“Garlic is antiviral, antibacterial, antifungal (including anti-mold), anti-parasitic, and rich in the phytochemical allicin, a sulfur compound that prevents disease.”\n\n“Garlic kills off pathogens such as viruses and unproductive bacteria, which are behind so many mystery and chronic illnesses and symptoms.”\n\n“Garlic helps fight colds, flus, strep throat, pneumonia-causing bacteria, and viral-related cancers.”\n\nFacebook Post Date January 9, 2022\n\n“Eat some garlic and lower that blood pressure!”\n\n“Garlic has anti-inflammatory benefits and helps blood flow more easily through the body. Several studies found that blood pressure was lowered by 10%!!!!”\n\nRosebud’s Elderberry Lemonade and Rosebud’s Fruit Butters Peach Blueberry (which contain lemon): www.facebook.com\u002FRosebudsRealFood\n\nFacebook Post Date February 19, 2022\n\n“[P]hytochemicals called limonoids in lemons and limes actually bond the vitamin C and calcium together, so that wherever one goes in the body, the other rides along. This enhances the bioavailability of each, and also creates alkalinity in the body to help prevent the growth of almost every type of cancer”\n\n“The antioxidant flavonoids in lemons and limes are another ally in fighting disease. And when you’re dealing with a cold, flu, bronchitis, or pneumonia, lemon is one of the most effective mucus expellers you can find.”\n\nYour products are not generally recognized as safe and effective for the above referenced uses and, therefore, the products are “new drugs” under section 201(p) of the Act [21 U.S.C. 321(p)]. With certain exceptions not applicable here, new drugs may not be legally introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in sections 301(d) and 505(a) of the Act [21 U.S.C. 331(d), 355(a)]. FDA approves a new drug on the basis of scientific data and information demonstrating that the drug is safe and effective.\n\nA drug is misbranded under section 502(f)(1) of the Act [21 U.S.C. 352(f)(1)] if the drug fails to bear adequate directions for its intended use(s). “Adequate directions for use” means directions under which a layperson can use a drug safely and for the purposes for which it is intended (21 CFR 201.5). Prescription drugs, as defined in section 503(b)(1)(A) of the Act [21 U.S.C. 353(b)(1)(A)], can only be used safely at the direction, and under the supervision, of a licensed practitioner.\n\nYour products Rosebud’s Natural Seasonings Elderberry Syrup Kit, Rosebud’s Elderberry Lemonade, Rosebud’s Real Food Raw! Habanero Sriracha, Rosebud’s Natural Seasonings Jane’s Italian, Rosebud’s Fruit Butters Peach Blueberry, Rosebud’s Herbs & Spices Sencha Tea and Rosebud’s Real Food Supertonic! Sriracha are intended for treatment of one or more diseases that are not amenable to self-diagnosis or treatment without the supervision of a licensed practitioner. Therefore, it is impossible to write adequate directions for a layperson to use your product safely for its intended purpose. Accordingly, Rosebud’s Natural Seasonings Elderberry Syrup Kit, Rosebud’s Elderberry Lemonade, Rosebud’s Real Food Raw! Habanero Sriracha, Rosebud’s Natural Seasonings Jane’s Italian, Rosebud’s Fruit Butters Peach Blueberry, Rosebud’s Herbs & Spices Sencha Tea, and Rosebud’s Real Food Supertonic! Sriracha fail to bear adequate directions for their intended use and, therefore, the products are misbranded under section 502(f)(1) of the Act [21 U.S.C. 352(f)(1)]. The introduction or delivery for introduction into interstate commerce of these misbranded drugs violates section 301(a) of the Act [21 U.S.C. 331(a)].\n\nThis letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\n\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\n\nPlease notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within 15 working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration.\n\nYour reply should be addressed to the U.S. Food and Drug Administration; Attn: Christopher N. Dedeaux, Compliance Officer, via email at ORAHAFEAST5FirmResponses@fda.hhs.gov or at 404 BNA Drive, Suite 500, Nashville, TN 37217. You may reach Mr. Dedeaux at 504-846-6122 or via email at Christopher.Dedeaux@fda.hhs.gov if you have any questions about this matter.\n\nSincerely,\n\n\u002FS\u002F\n\nSteven B. Barber\n\nDirector, Division V\n\nOffice of Human and Animal Foods Operations-East","Rosebud's Ranch and Garden, LLC","rosebuds-ranch-and-garden-llc-628567-10182022","2026-08-18T06:42:29.145918+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Frosebuds-ranch-and-garden-llc-628567-10182022","2026-10-26T08:09:51.131225+00:00","Closed Out","2022-11-22","628567","DrugsFood & Beverages","2023-04-07","Division of Human and Animal Food Operations East V","Amber R. Stephenson","2026-08-20T01:24:47.789+00:00","United Parcel Service","2022-10-18",{"id":80,"raw":81,"subject":87,"body_html":88,"body_text":89,"firm_name":90,"letter_id":91,"created_at":66,"fei_number":19,"letter_url":92,"updated_at":93,"action_type":22,"case_status":23,"posted_date":78,"marcs_cms_no":94,"product_type":95,"closeout_date":19,"issuing_office":85,"recipient_name":96,"body_fetched_at":97,"delivery_method":98,"recipient_title":19,"reference_number":19,"action_taken_date":99,"medical_device_id":19,"response_letter_date":19},2392,[82,83,84,85,86,13,13,13],"\u003Ctime datetime=\"2022-10-18T13:20:00Z\">10\u002F18\u002F2022\u003C\u002Ftime>\n","\u003Ctime datetime=\"2022-09-20T04:00:00Z\">09\u002F20\u002F2022\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fsouth-pork-ranch-equipment-llc-642420-09202022\">South Pork Ranch Equipment LLC\u003C\u002Fa>","Center for Veterinary Medicine","Unapproved New Animal Drug\u002FAdulterated\u003Cbr \u002F>\r\n","Unapproved New Animal Drug\u002FAdulterated","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Email\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Animal &amp; Veterinary\u003Cbr>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>James Fuller\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>eBay account: goatandchickenman\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>South Pork Ranch Equipment LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>(b)(6)\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Veterinary Medicine\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>September 20, 2022\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>RE: 642420\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Dear James Fuller:\u003C\u002Fp>\n\n\u003Cp>This letter concerns your firm’s marketing of unapproved animal drug products for the treatment of disease in animals, including but not limited to, Cydectin (moxidectin), Cydectin (moxidectin) with Blackstrap Iron Supplement, and Blackstrap. The U.S. Food and Drug Administration (FDA) has reviewed your account, “goatandchickenman”, at the internet address https:\u002F\u002Fwww.ebay.com\u002Fusr\u002Fgoatandchickenman, and Craigslist listing at the internet address https:\u002F\u002Fdallas.craigslist.org in August 2022 and have determined that you distribute these products on these websites. The claims on your accounts on the listed websites establish that your Cydectin, Cydectin with Blackstrap Iron Supplement, and “Blackstrap” products are drugs under section 201(g)(1)(B) of the FD&amp;C Act [21 U.S.C. 321(g)(1)(B)], because these products are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease in animals. As explained further below, these products are unapproved new animal drugs and introducing or introduction for delivery of these products into interstate commerce violates the Federal Food Drug and Cosmetic Act (FD&amp;C Act).\u003C\u002Fp>\n\n\u003Cp>You can find the FD&amp;C Act and FDA regulations through links on FDA’s homepage at \u003Ca>www.fda.gov.\u003C\u002Fa>\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Adulterated New Animal Drugs\u003C\u002Fstrong>\u003Cbr>\nExamples of claims FDA observed on eBay and Craigslist that show the intended uses of your “Cydectin cattle pour-on dewormer” product includes, but may not be limited to, the following:\u003C\u002Fp>\n\n\u003Cp>From your eBay store webpage titled – “Cydectin cattle pour-on dewormer 250 ml\u002Fcc Current …” (https:\u002F\u002Fwww.ebay.com\u002Fitm\u002FCydectin-cattle-pour-on-dewormer-250-ml-cc-Current-expiration-Sept-2023\u002F183106132479)\u003Cbr>\n• “Cydectin® - moxidectin - Pour-On for Beef and Dairy Cattle - Antiparasitic”\u003Cbr>\n• “South Pork Ranch Equipment – Cydectin 250 ml (cc) – Cattle-Pour-On, 10cc per 220 lbs body weight – Sheep &amp; Goats-\u003Cstrong>GIVE ORALLY\u003C\u002Fstrong>, 1 cc per 20 lbs body weight – Expiration Date… ”\u003C\u002Fp>\n\n\u003Cp>From your eBay store webpage titled – “Cydectin pour-on Cattle wormer 500 ml. …” (https:\u002F\u002Fwww.ebay.com\u002Fitm\u002FCydectin-pour-on-Cattle-wormer-500-ml-Current-expiration-Date-Sept-2023\u002F182514449076)\u003Cbr>\n• “South Pork Ranch Equipment, LLC – Cydectin 500 ml (cc) – Cattle-Pour-On, 10cc per 220 lbs body weight – Sheep &amp; Goats-\u003Cstrong>GIVE ORALLY\u003C\u002Fstrong>, 1 cc per 20 lbs body weight – Expiration Date 10\u002F2018_”\u003C\u002Fp>\n\n\u003Cp>From your eBay store webpage titled – “Goat medication - Cydectin dewormer + Blackstrap Iron Supplement” (https:\u002F\u002Fwww.ebay.com\u002Fitm\u002FGoat-medication-Cydectin-dewormer-Blackstrap-Iron-Supplement\u002F184241021511)\u003Cbr>\n• “Blackstrap as an iron supplement is very effective in treating Goats suffering anemia due to a heavy WORM infestation.”\u003Cbr>\n• “Stomach worms can suck the blood of the goat causing acute anemia, and death when the goat appears to be in good health. The most common of these is Haemonchus contortus (most common in spring and summer.) An infection of Haemonchus can cause death in a short a time as one week when there is heavy infestation, with few symptoms. In many cases, agressive [sic] treatment with Cydectin dewormer and Blackstrap molasses will save the life of the Goat.”\u003Cbr>\n• “It's recommended that heavy worm infestation be treated with CYDECTIN…”\u003Cbr>\n• “Goat medication - Cydectin dewormer + Blackstrap Iron Supplement”\u003Cbr>\n• “Cydectin® - moxidectin - Pour-On for Beef and Dairy Cattle - Antiparasitic”\u003C\u002Fp>\n\n\u003Cp>From your eBay store webpage titled – “Goat Suppliment [sic] \u002F Quickly rebuilds blood level loss due to worm infestation” (https:\u002F\u002Fwww.ebay.com\u002Fitm\u002FGoat-Suppliment-Quickly-rebuilds-blood-level-loss-due-to-worm-infestation\u002F184251657733)\u003Cbr>\n• “In many cases, aggressive [sic] treatment with Cydectin dewormer and Blackstrap molasses will save the life of the Goat. We highly recommend the use of Cydectin dewormer with this product.”\u003Cbr>\n• “Blackstrap is used to quickly rebuild blood but IS NOT used to deworm.”\u003Cbr>\n• “South Pork Ranch Equipment – Blackstrap 250 ml (cc) – Iron Supplement used in the treatment of GOATS suffering anemia due to a heavy worm infestation. – Give ORALLY, 1cc per 20lbs body weight twice a day.”\u003C\u002Fp>\n\n\u003Cp>From your Craigslist listing titled – “Cydectin wormer (500 ml) 50% Off goats – sheep – cattle (Will ship)…” (https:\u002F\u002Fdallas.craigslist.org\u002Fdal\u002Fgrd\u002Fd\u002Fterrell-cydectin-wormer-500-ml-50-off\u002F7517963485.html)\u003Cbr>\n• “Cydectin wormer (500 ml) 50% Off goats – sheep – cattle (Will ship) --$48”\u003Cbr>\n• “Cydectin® - moxidectin - Pour-On for Beef and Dairy Cattle - Antiparasitic”\u003Cbr>\n• “500 cc (ml) same quantity sell’s at Tractor supply for $99.99”\u003Cbr>\n• P.S. – safe for pregnant doe’s ewe’s heifer’s and “O” milk withdrawal.”\u003Cbr>\n• “tags: Sheep Goats goat Cattle Nubian Nubian Alpine alpine Doe’s doe Ewe’s Heifer’s bull bull’s Bull’s Bull bull’s Dorper dorper Dorper’s dorper’s Goat cows Cows cow Cow tractors cydectin dewormer Dewormer wormers Wormer”\u003C\u002Fp>\n\n\u003Cp>The claims quoted above are supplemented by the Craigslist tags used to bring consumers to your listing through Internet searches. Examples of the tags targeted to consumers who are looking for products to prevent or treat parasitic infections include: “cydectin” and “dewormer.”\u003C\u002Fp>\n\n\u003Cp>South Pork Equipment Cydectin and blackstrap molasses products are new animal drugs, as defined by section 201(v) of the FD&amp;C Act, [21 U.S.C. § 321(v)], because they are not generally recognized among experts qualified by scientific training and experience to evaluate the safety and effectiveness of animal drugs, as safe and effective for use under the conditions prescribed, recommended, or suggested in the labeling. To be legally marketed, a new animal drug must have an approved new animal drug application, conditionally approved new animal drug application, or index listing under sections 512, 571, and 572 of the FD&amp;C Act [21 U.S.C. §§ 360b, 360ccc, and 360ccc-1]. In addition, the drug product’s labeling must conform to the labeling approved in the application or index listing.\u003C\u002Fp>\n\n\u003Cp>We acknowledge that there is an approved pour-on product for cattle marketed by the application holder under the trade name Cydectin® (moxidectin). It is not clear if what you are selling is the approved product that you have repackaged and relabeled. Regardless, the approved product is not approved or labeled for use in sheep or goats or for oral administration, all uses listed in the labeling for the products you sell. We note also that on both your eBay and Craigslist webpages you have photographs of your Cydectin product alongside the FDA approved Cydectin® (moxidectin) product and product packaging, which may misleadingly imply that the product you are selling is the approved Cydectin®.\u003C\u002Fp>\n\n\u003Cp>The products you are distributing are not approved or index listed by FDA, and their labeling does not conform to an approval and, therefore, the products are unsafe within the meaning of section 512(a) of the FD&amp;C Act, [21 U.S.C. § 360b(a)], and adulterated under section 501(a)(5) of the FD&amp;C Act [21 U.S.C. § 351(a)(5)]. The introduction or delivery for introduction into interstate commerce of an adulterated drug is prohibited under section 301(a) of the FD&amp;C Act [21 U.S.C. § 331(a)].\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>This letter is not intended to be an all-inclusive statement of violations that may exist in connection with your product. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all the requirements of federal law, including FDA regulations. This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and\u002For injunction.\u003C\u002Fp>\n\n\u003Cp>Please notify this office, in writing, within fifteen (15) working days of the receipt of this letter of the steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete the corrective actions within fifteen (15) working days, state the reason for the delay and the time within which you will complete the correction. If you believe that your products are not in\u003Cbr>\nviolation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\n\n\u003Cp>Your response should be sent via e-mail to Dr. Vic Boddie at CVMUnapprovedDrugs@fda.hhs.gov. If you have any questions about this letter, please contact Dr. Boddie at that address.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Neal Bataller, ME, DVM\u003Cbr>\nDirector, Division of Drug Compliance\u003Cbr>\nOffice of Surveillance &amp; Compliance\u003Cbr>\nCenter for Veterinary Medicine\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Email\n\nProduct:\n\nAnimal & Veterinary\nDrugs\n\nRecipient:\n\nRecipient Name\n\nJames Fuller\n\nRecipient Title\n\neBay account: goatandchickenman\n\nSouth Pork Ranch Equipment LLC\n\n(b)(6)\n\nUnited States\n\nIssuing Office:\n\nCenter for Veterinary Medicine\n\nUnited States\n\nWARNING LETTER\n\nSeptember 20, 2022\n\nRE: 642420\n\nDear James Fuller:\n\nThis letter concerns your firm’s marketing of unapproved animal drug products for the treatment of disease in animals, including but not limited to, Cydectin (moxidectin), Cydectin (moxidectin) with Blackstrap Iron Supplement, and Blackstrap. The U.S. Food and Drug Administration (FDA) has reviewed your account, “goatandchickenman”, at the internet address https:\u002F\u002Fwww.ebay.com\u002Fusr\u002Fgoatandchickenman, and Craigslist listing at the internet address https:\u002F\u002Fdallas.craigslist.org in August 2022 and have determined that you distribute these products on these websites. The claims on your accounts on the listed websites establish that your Cydectin, Cydectin with Blackstrap Iron Supplement, and “Blackstrap” products are drugs under section 201(g)(1)(B) of the FD&C Act [21 U.S.C. 321(g)(1)(B)], because these products are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease in animals. As explained further below, these products are unapproved new animal drugs and introducing or introduction for delivery of these products into interstate commerce violates the Federal Food Drug and Cosmetic Act (FD&C Act).\n\nYou can find the FD&C Act and FDA regulations through links on FDA’s homepage at www.fda.gov.\n\nAdulterated New Animal Drugs\n\nExamples of claims FDA observed on eBay and Craigslist that show the intended uses of your “Cydectin cattle pour-on dewormer” product includes, but may not be limited to, the following:\n\nFrom your eBay store webpage titled – “Cydectin cattle pour-on dewormer 250 ml\u002Fcc Current …” (https:\u002F\u002Fwww.ebay.com\u002Fitm\u002FCydectin-cattle-pour-on-dewormer-250-ml-cc-Current-expiration-Sept-2023\u002F183106132479)\n\n• “Cydectin® - moxidectin - Pour-On for Beef and Dairy Cattle - Antiparasitic”\n\n• “South Pork Ranch Equipment – Cydectin 250 ml (cc) – Cattle-Pour-On, 10cc per 220 lbs body weight – Sheep & Goats-GIVE ORALLY, 1 cc per 20 lbs body weight – Expiration Date… ”\n\nFrom your eBay store webpage titled – “Cydectin pour-on Cattle wormer 500 ml. …” (https:\u002F\u002Fwww.ebay.com\u002Fitm\u002FCydectin-pour-on-Cattle-wormer-500-ml-Current-expiration-Date-Sept-2023\u002F182514449076)\n\n• “South Pork Ranch Equipment, LLC – Cydectin 500 ml (cc) – Cattle-Pour-On, 10cc per 220 lbs body weight – Sheep & Goats-GIVE ORALLY, 1 cc per 20 lbs body weight – Expiration Date 10\u002F2018_”\n\nFrom your eBay store webpage titled – “Goat medication - Cydectin dewormer + Blackstrap Iron Supplement” (https:\u002F\u002Fwww.ebay.com\u002Fitm\u002FGoat-medication-Cydectin-dewormer-Blackstrap-Iron-Supplement\u002F184241021511)\n\n• “Blackstrap as an iron supplement is very effective in treating Goats suffering anemia due to a heavy WORM infestation.”\n\n• “Stomach worms can suck the blood of the goat causing acute anemia, and death when the goat appears to be in good health. The most common of these is Haemonchus contortus (most common in spring and summer.) An infection of Haemonchus can cause death in a short a time as one week when there is heavy infestation, with few symptoms. In many cases, agressive [sic] treatment with Cydectin dewormer and Blackstrap molasses will save the life of the Goat.”\n\n• “It's recommended that heavy worm infestation be treated with CYDECTIN…”\n\n• “Goat medication - Cydectin dewormer + Blackstrap Iron Supplement”\n\n• “Cydectin® - moxidectin - Pour-On for Beef and Dairy Cattle - Antiparasitic”\n\nFrom your eBay store webpage titled – “Goat Suppliment [sic] \u002F Quickly rebuilds blood level loss due to worm infestation” (https:\u002F\u002Fwww.ebay.com\u002Fitm\u002FGoat-Suppliment-Quickly-rebuilds-blood-level-loss-due-to-worm-infestation\u002F184251657733)\n\n• “In many cases, aggressive [sic] treatment with Cydectin dewormer and Blackstrap molasses will save the life of the Goat. We highly recommend the use of Cydectin dewormer with this product.”\n\n• “Blackstrap is used to quickly rebuild blood but IS NOT used to deworm.”\n\n• “South Pork Ranch Equipment – Blackstrap 250 ml (cc) – Iron Supplement used in the treatment of GOATS suffering anemia due to a heavy worm infestation. – Give ORALLY, 1cc per 20lbs body weight twice a day.”\n\nFrom your Craigslist listing titled – “Cydectin wormer (500 ml) 50% Off goats – sheep – cattle (Will ship)…” (https:\u002F\u002Fdallas.craigslist.org\u002Fdal\u002Fgrd\u002Fd\u002Fterrell-cydectin-wormer-500-ml-50-off\u002F7517963485.html)\n\n• “Cydectin wormer (500 ml) 50% Off goats – sheep – cattle (Will ship) --$48”\n\n• “Cydectin® - moxidectin - Pour-On for Beef and Dairy Cattle - Antiparasitic”\n\n• “500 cc (ml) same quantity sell’s at Tractor supply for $99.99”\n\n• P.S. – safe for pregnant doe’s ewe’s heifer’s and “O” milk withdrawal.”\n\n• “tags: Sheep Goats goat Cattle Nubian Nubian Alpine alpine Doe’s doe Ewe’s Heifer’s bull bull’s Bull’s Bull bull’s Dorper dorper Dorper’s dorper’s Goat cows Cows cow Cow tractors cydectin dewormer Dewormer wormers Wormer”\n\nThe claims quoted above are supplemented by the Craigslist tags used to bring consumers to your listing through Internet searches. Examples of the tags targeted to consumers who are looking for products to prevent or treat parasitic infections include: “cydectin” and “dewormer.”\n\nSouth Pork Equipment Cydectin and blackstrap molasses products are new animal drugs, as defined by section 201(v) of the FD&C Act, [21 U.S.C. § 321(v)], because they are not generally recognized among experts qualified by scientific training and experience to evaluate the safety and effectiveness of animal drugs, as safe and effective for use under the conditions prescribed, recommended, or suggested in the labeling. To be legally marketed, a new animal drug must have an approved new animal drug application, conditionally approved new animal drug application, or index listing under sections 512, 571, and 572 of the FD&C Act [21 U.S.C. §§ 360b, 360ccc, and 360ccc-1]. In addition, the drug product’s labeling must conform to the labeling approved in the application or index listing.\n\nWe acknowledge that there is an approved pour-on product for cattle marketed by the application holder under the trade name Cydectin® (moxidectin). It is not clear if what you are selling is the approved product that you have repackaged and relabeled. Regardless, the approved product is not approved or labeled for use in sheep or goats or for oral administration, all uses listed in the labeling for the products you sell. We note also that on both your eBay and Craigslist webpages you have photographs of your Cydectin product alongside the FDA approved Cydectin® (moxidectin) product and product packaging, which may misleadingly imply that the product you are selling is the approved Cydectin®.\n\nThe products you are distributing are not approved or index listed by FDA, and their labeling does not conform to an approval and, therefore, the products are unsafe within the meaning of section 512(a) of the FD&C Act, [21 U.S.C. § 360b(a)], and adulterated under section 501(a)(5) of the FD&C Act [21 U.S.C. § 351(a)(5)]. The introduction or delivery for introduction into interstate commerce of an adulterated drug is prohibited under section 301(a) of the FD&C Act [21 U.S.C. § 331(a)].\n\nConclusion\n\nThis letter is not intended to be an all-inclusive statement of violations that may exist in connection with your product. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all the requirements of federal law, including FDA regulations. This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and\u002For injunction.\n\nPlease notify this office, in writing, within fifteen (15) working days of the receipt of this letter of the steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete the corrective actions within fifteen (15) working days, state the reason for the delay and the time within which you will complete the correction. If you believe that your products are not in\n\nviolation of the FD&C Act, include your reasoning and any supporting information for our consideration.\n\nYour response should be sent via e-mail to Dr. Vic Boddie at CVMUnapprovedDrugs@fda.hhs.gov. If you have any questions about this letter, please contact Dr. Boddie at that address.\n\nSincerely,\n\n\u002FS\u002F\n\nNeal Bataller, ME, DVM\n\nDirector, Division of Drug Compliance\n\nOffice of Surveillance & Compliance\n\nCenter for Veterinary Medicine","South Pork Ranch Equipment LLC","south-pork-ranch-equipment-llc-642420-09202022","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fsouth-pork-ranch-equipment-llc-642420-09202022","2026-10-26T08:10:02.08888+00:00","642420","Animal & VeterinaryDrugs","James Fuller","2026-08-20T01:30:20.308+00:00","Via Email","2022-09-20",4,{"510k":102,"classification":103,"enforcement":104,"event":105,"event_backfill":106,"pma":107,"warning_letter":108},"2026-11-16T02:00:55.89+00:00","2026-11-16T02:00:41.999+00:00","2026-11-16T02:00:49.415+00:00","2026-11-18T04:00:44.748+00:00","2026-09-07T05:17:28.839+00:00","2026-11-16T02:01:03.155+00:00","2026-11-17T01:02:55.859+00:00"]